Business Context and Reporting Period
This Form 8-K Current Report, dated May 19, 2026, pertains to Amgen Inc. (AMGN). The filing discloses significant executive leadership changes within the finance function, specifically the retirement of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
The filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data provided relates exclusively to the compensation package for the newly appointed CFO, Thomas Dittrich, denominated in Swiss Francs (CHF):
- Annual Base Salary: CHF 1,070,000
- Target Annual Incentive: 100% of base salary
- 2026 Long-Term Equity Target Value: CHF 4,500,000 (comprising stock options, RSUs, and performance units)
- One-Time RSU Award (Foregone Compensation): CHF 4,700,000
- One-Time Cash Bonus (Foregone Compensation): CHF 4,000,000
- Two-Year Retention Bonus: CHF 5,800,000 (repayable pro-rata upon early departure)
- Relocation Allowance: CHF 250,000
Material Changes
The primary material change is the transition of the CFO role:
- Departure: Peter H. Griffith will retire as Executive Vice President and CFO effective August 31, 2026. He will remain as a non-executive officer until January 31, 2027.
- Appointment: Thomas Dittrich is appointed to succeed Mr. Griffith. He will serve as a non-executive officer from July 1, 2026, and assume the role of Executive Vice President and CFO on September 1, 2026.
- Location: Mr. Dittrich will initially be based in Rotkreuz, Switzerland, before relocating to Thousand Oaks, California, in September 2026.
Outlook, Risks, and Contingencies
Management Commentary and Background: Mr. Dittrich brings experience as CFO of Galderma Group AG (since 2019), Shire Pharmaceuticals, and Sulzer AG. He previously worked at Amgen from 2006 to 2014. He reports directly to CEO Robert A. Bradway.
Contingencies and Risks:
- Retention Bonus Repayment: The CHF 5,800,000 retention bonus is subject to clawback on a pro-rata basis if Mr. Dittrich resigns or is terminated for misconduct within two years of his hire date.
- Severance Protection: Mr. Dittrich is eligible for severance equal to two times his salary and target bonus if terminated without cause within two years of his hire date.
Investor Verification Checklist
- Verify the exact vesting schedules and performance metrics for the CHF 4,500,000 long-term incentive awards and the CHF 4,700,000 one-time RSU award.
- Review the full text of the Employment Offer Agreement (Exhibit 10.1) and Expatriate Assignment Letter (Exhibit 10.2) for detailed terms regarding tax equalization and specific relocation benefits.
- Confirm the timeline for the transition of duties between Mr. Griffith and Mr. Dittrich to ensure no gap in financial reporting oversight.
- Monitor future filings for the impact of the one-time cash bonus and equity grants on Amgen's share count and compensation expense.